Important advances in knowledge about the treatment of heart failure (HF) have been made over the past three decades. In the 1980s, direct vasodilators, such as hydralazine and nitrate, and angiotensin-converting enzyme inhibitors (ACEis) were available. These drugs proved to be effective in the treatment of patients with different functional classes of HF. In CONSENSUS study, enalapril significantly reduced mortality, in patients with New York Heart Association (NYHA) class IV; number needed to treat – NNT, 6. as well as […]